Table 1 Effect of BRCA1 and BRCA2 mutations on bladder cancer risk
From: Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
Mutation subjects | Number of carriers/total (frequency %) | OR | 95% CI | p-value |
|---|---|---|---|---|
BRCA1 | ||||
5328 insC | ||||
Controls | 14/4000 (0.003) | 1.0 | ||
Cases | 3/1028 (0.003) | 0.8 | 0.23–2.90 | 0.8 |
C61G | ||||
Controls | 2/4000 (0.0005) | 1.0 | ||
Cases | 2/1028 (0.002) | 3.9 | 0.54–27.7 | 0.4 |
4153 delA | ||||
Controls | 1/4000 (0.0002) | 1.0 | ||
Cases | 0/1028 | – | – | – |
All BRCA1 | ||||
Controls | 17/4000 (0.004) | 1.0 | ||
Cases | 5/1028 (0.005) | 1.1 | 0.42–3.11 | 1.0 |
BRCA2 | ||||
C5972T | ||||
Controls | 159/2791(0.06) | 1.0 | ||
Cases | 54/1028 (0.05) | 0.9 | 0.66–1.26 | 0.6 |